|
|
|
|
 |
|
Ardea to Present Data on Lead HIV Candidate, RDEA806, at XVII International AIDS Conference |
| 7/17/2008 @ 7:24 AM
print this article -
email to a friend -
join our eNewsletter
|
 |
Ardea Biosciences, Inc. (NASDAQ:RDEA) today announced that Dr. Graeme Moyle, Director of HIV Research, Chelsea and Westminster Hospital, will present results from the Phase 2a proof-of-concept monotherapy study of RDEA806, during an oral presentation at a late breaker session of the XVII International AIDS Conference in Mexico City on August 7, 2008. RDEA806 is the Company's novel investigational non-nucleoside reverse transcriptase inhibitor (NNRTI) for patients with human immunodeficiency virus (HIV).
Presentation Details
Date/Time: Thursday, August 7, 2008 from 2:30 p.m. - 4:00 p.m. CDT Abstract Title: "Antiviral activity of RDEA806, a novel HIV non-nucleoside reverse transcriptase inhibitor, in treatment of naive HIV patients" Session Title: THAB04 - Late Breaker Track B, Session 2 Location: Centro Banamex -- Session Room 1 (Abstract #THAB0403)
About Ardea Biosciences, Inc.
Ardea Biosciences, Inc., of San Diego, California, is a biotechnology company focused on the discovery and development of small-molecule therapeutics for the treatment of HIV, cancer and inflammatory diseases, including gout. We have four drug candidates in clinical trials and others in preclinical development and discovery. Our most advanced development candidate is RDEA806, a non-nucleoside reverse transcriptase inhibitor (NNRTI), which has successfully completed a Phase 2a study for the treatment of patients with HIV. We have evaluated our second-generation NNRTI for the treatment of HIV, RDEA427, in a human micro-dose pharmacokinetic study and have selected it as a development candidate. RDEA594, our lead development candidate for the treatment of gout, is in preclinical development and is believed to be an inhibitor of the URAT1 transporter in the kidney, which is responsible for regulation of uric acid levels. We are evaluating our lead MEK inhibitor, RDEA119, in a Phase 1 study in advanced cancer patients, as well as in a Phase 1 study in normal healthy volunteers as a precursor to trials in patients with inflammatory diseases. Lastly, we have evaluated our second-generation MEK inhibitor for the treatment of cancer and inflammatory diseases, RDEA436, in a human micro-dose pharmacokinetic study and have selected it as a development candidate. |
| BioTech / BioMedical / Medical |
|
|
| |
| Friday, September 5, 2008 |
 |
|
Gen-Probe to Webcast Presentation at the Morgan Stanley Global Healthcare Unplugged Conference Posted 3:28 PM PST
ACADIA Pharmaceuticals Files Registration Statement as Required by Previously Announced Committed Equity Financing Facility Posted 3:18 PM PST
Digirad Corporation Developing New Cardiac Imaging System With Distortion Correction Posted 7:39 AM PST
|
| |
| Thursday, September 4, 2008 |
|
|
ZyGEM and Commonwealth Biotechnologies Announce Research Collaboration for DNA Extraction Products Posted 3:42 PM PST
Aethlon Medical Releases Shareholder Letter Posted 2:43 PM PST
Cypress Bioscience, Inc. to Participate in Citi's 3rd Annual Biotech Day Posted 7:59 AM PST
CliniComp Announces Agreement with Tenet Healthcare Corporation Posted 7:34 AM PST
Invitrogen Launches Patent Licensing Program for Enabling Amplification Technology Posted 7:29 AM PST
Isis Receives Notices of Allowance That Significantly Expand the Scope of Key RNA Therapeutic Patents Posted 7:02 AM PST
|
| |
| Wednesday, September 3, 2008 |
|
|
NuVasive to Present at Bank of America 38th Annual Investment Conference Posted 3:16 PM PST
Alacer Corp. Announces Emergen-C PINK College Tour to Build Breast Cancer Awareness Posted 3:08 PM PST
Nventa to Present at Upcoming Investor Conferences Posted 3:06 PM PST
Neurocrine Biosciences Announces Successful Elagolix PETAL Study in Endometriosis Posted 3:04 PM PST
|
| |
| Tuesday, September 2, 2008 |
|
|
Neurocrine Biosciences Announces Successful Elagolix PETAL Study in Endometriosis Posted 5:34 PM PST
Catheter Ablation System for Atrial Fibrillation Shows Reduced Procedure Time, Remarkable Safety Profile and Excellent Outcomes in Two Clinical Studies Posted 5:07 PM PST
NuVasive to Present at Morgan Stanley Global Healthcare Unplugged Conference Posted 5:01 PM PST
Somaxon Presents Pharmacological Data on Doxepin at the 21st European College of Neuropsychopharmacology Congress Posted 4:18 PM PST
NuVasive to Present at Thomas Weisel Partners Healthcare Conference 2008 Posted 9:12 AM PST
Volcano's VH(R) IVUS Technology Used in Imaging Study of GlaxoSmithKline's Novel Investigational Compound, Darapladib Posted 8:41 AM PST
Sequenom to Present at September Investment Conferences and to Hold Analyst and Investor Briefing Event Posted 8:12 AM PST
Aethlon Medical To Present at 2008 Southern California Investor Conference Southern California Investor Conference 2008 Posted 8:10 AM PST
Optimer Pharmaceuticals Completes Enrollment in Second Prulifloxacin Phase 3 Clinical Trial Posted 8:08 AM PST
Burnham Awarded $97.9 Million NIH Grant to Expand Small-Molecule Screening and Discovery Center Posted 7:47 AM PST
|
| |
| Thursday, August 28, 2008 |
|
|
Orexigen Therapeutics to Present at Upcoming Investor Conferences Posted 3:16 PM PST
Amylin Pharmaceuticals to Present at Thomas Weisel Healthcare, BioCentury NewsMakers, and Morgan Stanley Global Healthcare Conferences Posted 3:15 PM PST
Cadence Pharmaceuticals' CEO Theodore Schroeder to Present at the 2008 NewsMakers In the Biotech Industry Conference Posted 3:14 PM PST
Arena Pharmaceuticals to Present at the NewsMakers in the Biotech Industry Conference Posted 3:13 PM PST
Volcano Presentation at Thomas Weisel Conference to Be Webcast Posted 3:12 PM PST
Gen-Probe to Webcast Presentation at the Thomas Weisel Partners Healthcare Conference 2008 Posted 3:12 PM PST
Illumina to Present at Upcoming Investment Conferences in September Posted 7:43 AM PST
Optimer Pharmaceuticals to Present at BioCentury NewsMakers Conference Posted 7:42 AM PST
ACADIA Pharmaceuticals to Present at The Thomas Weisel Partners Healthcare Conference on September 4, 2008 Posted 7:42 AM PST
|
| |
| Wednesday, August 27, 2008 |
|
|
Genoptix Announces Participation at the 2008 Southern California Investor Conference Posted 9:08 AM PST
|
| |
| Tuesday, August 26, 2008 |
|
|
Amylin Pharmaceuticals and Eli Lilly Provide Context for FDA Alert for BYETTA Posted 3:42 PM PST
Cyntellect to Collaborate With the Burnham Institute for Medical Research; In situ live cell manipulation on LEAP to empower purification of stem cells and their differentiated progeny Posted 8:57 AM PST
TorreyPines Therapeutics Receives NASDAQ Deficiency Notice Posted 8:50 AM PST
JMAR Technologies Awarded Development Contract by the Johns Hopkins University Applied Physics Laboratory Posted 8:29 AM PST
Aperio Receives FDA Clearance for ER and PR Image Analysis Applications Posted 7:52 AM PST
|
| |
| Monday, August 25, 2008 |
|
|
Amylin and Lilly Set Date and Time for Conference Call; Companies Will Discuss Recent FDA Advisory Regarding BYETTA Posted 4:17 PM PST
Cripps Translational Science Institute Contributes to Discovery of Predisposition Gene for Childhood Cancer Posted 4:13 PM PST
Neurocrine Biosciences to Present at Thomas Weisel Healthcare Conference and the NewsMakers in the Biotech Industry Conference Posted 4:12 PM PST
Invitrogen Sets Date for Special Meeting of Shareholders to Vote on Proposed Merger with Applied Biosystems Posted 6:15 AM PST
|
|
|
|
|
|
FreshNews.com Jobs Change DAILY
We Have 5,000 + Job Listings! Open Your FREE Account
Employers or Job Searchers Get Started Now! Click Here
|
